HLA
NKTR icon

Hamilton Lane Advisors’s Nektar Therapeutics NKTR Stock Holding History

Hamilton Lane Advisors’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-2,431
Closed -$565K – 58
2014
Q4 		$565K Buy
+2,431
New +$520K 0.21% 39

Other funds holding NKTR

O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Hamilton Lane Advisors's NKTR Position: Q1 2015 in Review

Hamilton Lane Advisors sold out of Nektar Therapeutics (NKTR) in Q1 2015, closing a stake of 2,431 shares — an estimated $565K sold.

Hamilton Lane Advisors first reported a position in NKTR in Q4 2014 and held it in 1 quarter. The position peaked at $565K in Q4 2014. 153 funds tracked by Wall St. Rank hold NKTR as of Q1 2015.

  • Hamilton Lane Advisors reported no remaining Nektar Therapeutics position as of Q1 2015 after selling out during the quarter.
  • Hamilton Lane Advisors sold 2,431 Nektar Therapeutics shares in Q1 2015, an estimated $565K.
  • Hamilton Lane Advisors first reported a position in Nektar Therapeutics in Q4 2014 and held it in 1 quarter.
  • Hamilton Lane Advisors's Nektar Therapeutics position peaked at $565K in Q4 2014.
  • 153 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q1 2015.

Based on Hamilton Lane Advisors's 13F filing for Q1 2015, filed 8 Apr 2015.